Aged, you are one in this thread that said SNY would not take back Afrezza because they would be sued if they did. I'm just saying if SNY would again become part of Aftezza, via with Onduo or other means, and a law suit against them by whomever (MNKD share holders perhaps) would result, it would not be a big deal for SNY.
Hence I don't think the threat of a law suit would be a deterence for SNY or Verily to partner with Afrezza or buy out MNKD.
Ah, wrong law suit I thought that was Mannkind suing Sanofi (again!)
You are correct, Mannkind shareholders could sue Mannkind. It's all academic though because buying Afrezza does not fit Onduo's business plan any more than buying a generic would. Onduo is about data and management, management not about specific drugs
From Onduo's point of view they will be far more interested in injectables since that is what almost everyone uses and hence data sets exist. If you are trying to solve problem at scale then you need to go where treatments exist at scale. In later years when Afrezza becomes a significant player then they will be interested but right now the population is far to small to get meaningful results from at scale.
[
No Aged, I was referring to MNKD shareholders suing SNY if SNY were to buyout MNKD for Afrezza or.... regardless....
I think you are most likely correct about Onduo, but Onduo has a mission to make it easier for diabetics to care for themselves (including perhpas how and when to take, how much, and what type of insulin, and are working towards holistic treatments). Onduo is working with data analysis and with a couple of healthcare providers in an effort to come up with ways to reduce costs and increase the quality of life for diabetics. They are most probably gathering Afrezza data as they are focused on methods of use that will benefit patients and healthcare companies. If Afrezza is what many make it out to be, I would think this to be very positive for MNKD. It seems to me SNY would be helping Onduo at this moment with data on Afrezza just as they would be for other diabetes medications? Perhaps a year or two down the road and SNY might reenter the Afrezza picture. But who knows, just saying it's a possibility. .
From Verily's website
"What we do
Verily lives at the intersection of technology, data science and healthcare.
Our mission is to make the world's health data useful so that people enjoy healthier lives.
Verily is developing tools to collect and organize health data, then creating interventions and platforms that put insights derived from that health data to use for more holistic care management. We have three guiding product design principles: start with the user, simplify care, and lead on security and privacy."